Secukinumab-treated patients in the PURE registry (Patients with Moderate to Severe Chronic Plaque Psoriasis in Latin America and Canada): 12-month follow-up data - 03/08/18
Charles W. Lynde, MD, Lynde Institute for Dermatology, University of Toronto, and Probity Medical Research; Kim Alexander Papp, MD, PhD, K. Papp Clinical Research and Probity Medical Research; Melinda Gooderham, MD, SKiN Center for Dermatology, Queen’s University, and Probity Medical Research; Afsaneh Alavi, MD, Afsaneh Alavi Medicine Professional Corp. and Probity Medical Research; Jennifer Beecker, MD, Division of Dermatology, University of Ottawa; Norman Wasel, MD, Probity Medical Research and Stratica Medical; Emmanouil Rampakakis, PhD, JSS Medical Research; Valerie Gregry, Novartis Pharmaceuticals Canada; Shamiza Hussein, Novartis Pharmaceuticals Canada; Lenka Rihakova, PhD, Novartis Pharmaceuticals Canada
Le texte complet de cet article est disponible en PDF.| Commercial support: Novartis Pharmaceuticals Canada, Inc. |
Vol 79 - N° 3S1
P. AB257 - septembre 2018 Retour au numéro
Article précédent
- Secukinumab shows sustained efficacy in difficult-to-treat palmoplantar, nail, and scalp psoriasis: Long-term results from three phase III placebo-controlled randomized trials
- Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: Baseline characteristics, previous therapies, and transition periods of the first 2,000 subjects in the PROSPECT study
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?